IRIS
DE LUCA, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.690
NA - Nord America 4.454
AS - Asia 3.995
SA - Sud America 863
Continente sconosciuto - Info sul continente non disponibili 419
AF - Africa 85
OC - Oceania 3
Totale 15.509
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.230
RU - Federazione Russa 2.777
SG - Singapore 1.316
CN - Cina 1.309
BR - Brasile 713
IT - Italia 710
RO - Romania 700
SE - Svezia 474
HK - Hong Kong 469
VN - Vietnam 363
DE - Germania 269
FR - Francia 203
BD - Bangladesh 152
GB - Regno Unito 132
CA - Canada 114
FI - Finlandia 108
IN - India 84
NL - Olanda 81
AR - Argentina 64
AT - Austria 58
JP - Giappone 50
MX - Messico 50
PL - Polonia 42
ZA - Sudafrica 35
TR - Turchia 34
ES - Italia 33
ID - Indonesia 31
PH - Filippine 28
IQ - Iraq 24
EC - Ecuador 22
VE - Venezuela 19
CO - Colombia 17
PK - Pakistan 17
UA - Ucraina 17
LT - Lituania 16
AE - Emirati Arabi Uniti 14
JM - Giamaica 14
MY - Malesia 14
UZ - Uzbekistan 14
IE - Irlanda 13
CR - Costa Rica 12
EG - Egitto 12
PY - Paraguay 12
KR - Corea 11
MA - Marocco 10
TN - Tunisia 10
BE - Belgio 9
NP - Nepal 9
CL - Cile 7
GR - Grecia 7
IR - Iran 7
PE - Perù 7
BH - Bahrain 6
NI - Nicaragua 6
NO - Norvegia 6
SA - Arabia Saudita 6
AZ - Azerbaigian 5
HN - Honduras 5
LU - Lussemburgo 5
MK - Macedonia 5
BG - Bulgaria 4
CH - Svizzera 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
IL - Israele 4
KE - Kenya 4
KZ - Kazakistan 4
LB - Libano 4
XK - ???statistics.table.value.countryCode.XK??? 4
AU - Australia 3
DZ - Algeria 3
JO - Giordania 3
LV - Lettonia 3
PR - Porto Rico 3
PT - Portogallo 3
SV - El Salvador 3
TH - Thailandia 3
AO - Angola 2
BB - Barbados 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
EU - Europa 2
HR - Croazia 2
HU - Ungheria 2
KH - Cambogia 2
MN - Mongolia 2
OM - Oman 2
PS - Palestinian Territory 2
SN - Senegal 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AL - Albania 1
AM - Armenia 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
CU - Cuba 1
CY - Cipro 1
Totale 15.086
Salva come PNG Salva come JPEG
Città #
Dallas 1.111
Singapore 678
Moscow 551
Ashburn 490
Hong Kong 457
San Jose 391
Shanghai 258
Beijing 208
Council Bluffs 184
New York 183
Milan 158
Hefei 156
Lauterbourg 133
Ho Chi Minh City 129
Los Angeles 119
Lawrence 99
Princeton 99
Munich 96
Santa Clara 93
São Paulo 78
Boardman 63
Hanoi 62
Nuremberg 62
Helsinki 60
Rome 60
Orem 43
Tokyo 40
Atlanta 35
Denver 35
Warsaw 35
Chicago 34
Montreal 32
Johannesburg 29
Rio de Janeiro 29
Chennai 28
Frankfurt am Main 28
Phoenix 27
Turku 27
Da Nang 26
Guangzhou 26
Seattle 25
Mexico City 24
Cesano Boscone 23
Poplar 23
Stockholm 23
Buffalo 21
Houston 21
Lappeenranta 20
London 20
Boston 19
Brooklyn 19
Falkenstein 19
Toronto 19
Haiphong 18
Amsterdam 17
Ankara 17
Manchester 17
Vienna 17
Naples 16
Mumbai 15
Omaha 15
Tianjin 15
Shenzhen 13
The Dalles 13
City of London 12
New Delhi 12
Secaucus 12
Tashkent 12
Belo Horizonte 11
Brescia 11
Campinas 11
Dublin 11
Hangzhou 11
Istanbul 11
Las Vegas 10
Padua 10
Porto Alegre 10
Verona 10
Xi'an 10
Can Tho 9
Columbus 9
Makati City 9
San Francisco 9
Brasília 8
Brussels 8
Florence 8
Guayaquil 8
Kuala Lumpur 8
Newark 8
Pietra Ligure 8
Pune 8
Roubaix 8
San José 8
Seongnam-si 8
Barnet 7
Biên Hòa 7
Bologna 7
Curitiba 7
Dhaka 7
Manaus 7
Totale 7.231
Salva come PNG Salva come JPEG
Nome #
Digital Ulcers and Ventricular Arrhythmias as Red Flags to Predict Replacement Myocardial Fibrosis in Systemic Sclerosis 464
Intercalated Disc Abnormalities Are Linked to Arrhythmias in Inflammatory Cardiomyopathy 446
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 395
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 350
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 278
Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in systemic sclerosis: Frequency, clinical and prognostic correlates 237
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 212
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 184
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 181
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 178
Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities 168
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 160
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 155
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 146
B cells in systemic sclerosis: A possible target for therapy 143
Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature 137
Distinctive clinical traits of lupus-related myocarditis: a multicentre retrospective study 137
Does the impact of COVID-19 on patients with systemic sclerosis change over time? 135
Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis 135
Exercise Stress Test Late after Arrhythmic versus Nonarrhythmic Presentation of Myocarditis 131
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study 130
Arrhythmias in Myocarditis: State of the Art 124
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 124
Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation 124
Pruritus characteristics in a large Italian cohort of psoriatic patients 122
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 122
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 121
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease 118
A Novel Histiocytosis With Synovial and Skin Involvement 118
Therapeutic strategies for primary heart involvement in systemic sclerosis 117
Clinical profiling and outcomes of viral myocarditis manifesting with ventricular arrhythmias 116
Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy 116
ASSOCIAZIONE TRA MALATTIA IGG4-CORRELATA E IMMUNOTERAPIA ALLERGENE-SPECIFICA. STUDIO EPIDEMIOLOGICO DI UN CENTRO DI RIFERIMENTO ITALIANO. 116
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 115
Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis 114
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 114
Drug retention rates of biological agents in adult onset Still's disease 114
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study 113
C3-glomerulopathy and MGUS: The skin beyond the kidney 112
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 112
Calcinosis in systemic sclerosis: An update on pathogenesis, related complications, and management: A heavy burden still waiting to be lifted off patients’ hands 110
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 109
Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al 109
Cardiovascular magnetic resonance parametric mapping in the risk stratification of patients affected by chronic myocarditis 109
Cardiac Safety of mRNA-based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis 108
Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases 106
Advances in potential targeted therapies for Erdheim-Chester disease 105
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 104
The spectrum of covid-19-associated myocarditis: A patient-tailored multidisciplinary approach 104
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 103
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 103
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 103
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 101
Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis 100
Inflammation as a Predictor of Recurrent Ventricular Tachycardia After Ablation in Patients With Myocarditis 100
Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers 100
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 99
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 98
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 97
Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias 97
Cardiac Sarcoidosis: Clinical Insights, Diagnosis, and Management Strategies 96
Pain and Frailty in Hospitalized Older Adults 96
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 96
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 96
Multimodal Detection and Targeting of Biopsy-Proven Myocardial Inflammation in Genetic Cardiomyopathies: A Pilot Report 95
Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases 94
Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum 94
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies 94
Cardiac involvement, a threatening very early manifestation of systemic sclerosis: evidence from VEDOSS patients 93
Anti-Ku syndrome with elevated CK: Association with myocardial involvement in systemic sclerosis 92
Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies 90
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients 89
Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series 89
Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis 89
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study 88
Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study 88
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 88
Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group 82
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 82
The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis 82
Unraveling the Pathogenesis of Calcinosis in Systemic Sclerosis: A Molecular and Clinical Insight 81
Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both 81
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition 81
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 80
Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis 79
Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review 79
Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis 78
The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry 78
Corrigendum to “Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience” [Autoimmunity Reviews, Volume 20, Issue 12, December 2021, 102981](S1568997221002615)(10.1016/j.autrev.2021.102981) 76
Ventricular Arrhythmias in Myocarditis: Characterization and Relationships With Myocardial Inflammation 76
MAVRILIMUMAB IMPROVES OUTCOMES IN SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION 76
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study 75
Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst 75
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 74
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry 73
Telemedicine in myocarditis: Evolution of a mutidisciplinary “disease unit” at the time of COVID-19 pandemic 73
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies 73
Data standards for transcatheter aortic valve implantation: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) (October, qcac063, 2022) 71
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli 71
Hybrid FDG-PET/MR or FDG-PET/CT to Detect Disease Activity in Patients With Persisting Arrhythmias After Myocarditis 71
Totale 12.133
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.906
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.906
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022248 0 0 102 46 9 16 4 7 11 31 5 17
2022/2023784 250 176 55 4 16 97 40 72 35 11 15 13
2023/2024744 25 56 75 67 65 111 42 82 5 33 36 147
2024/20253.364 224 41 102 104 130 218 1.093 331 388 233 200 300
2025/20269.539 612 868 944 1.147 707 286 724 665 2.473 491 293 329
2026/2027742 374 368 0 0 0 0 0 0 0 0 0 0
Totale 15.509